APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenza Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Influenza Treatment Market Outlook and Growth Opportunities 2026

21 December 2025196 pages

Choose your research edition.

Industry ResearchInfluenza Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza Treatment Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Influenza Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza Treatment Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Influenza Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Influenza Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Influenza Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Influenza Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Influenza Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Influenza Treatment market include Sanofi, Novartis AG, GSK plc., Daiichi Sankyo, AstraZeneca, Viatris Inc. (Mylan), Teva Pharmaceutical Industries Ltd., Roche Holding and NATCO Pharma Limited, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Influenza Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Influenza Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Influenza Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Influenza Treatment market.

Influenza Treatment Segment by Company

Sanofi

Novartis AG

GSK plc.

Daiichi Sankyo

AstraZeneca

Viatris Inc. (Mylan)

Teva Pharmaceutical Industries Ltd.

Roche Holding

NATCO Pharma Limited

Gilead Sciences

BioCryst Pharmaceuticals

Influenza Treatment Segment by Type

Zanamivir

Peramivir

Oseltamivir Phosphate

Baloxavir Marboxil

Others

Influenza Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Influenza Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Influenza Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Influenza Treatment key companies, revenue, market share, and recent developments.

3. To split the Influenza Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Influenza Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Influenza Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Influenza Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Influenza Treatment industry.

Chapter 3: Detailed analysis of Influenza Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Influenza Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Influenza Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Influenza Treatment Industry Trends Table 2. Influenza Treatment Industry Drivers Table 3. Influenza Treatment Industry Opportunities and Challenges Table 4. Influenza Treatment Industry Restraints Table 5. Global Influenza Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Influenza Treatment Revenue Share by Company (2021-2026) Table 7. Global Influenza Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Influenza Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Influenza Treatment Company, Product Type & Application Table 10. Global Influenza Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Influenza Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Zanamivir Table 15. Significant Companies of Peramivir Table 16. Significant Companies of Oseltamivir Phosphate Table 17. Significant Companies of Baloxavir Marboxil Table 18. Significant Companies of Others Table 19. Global Influenza Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Influenza Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Influenza Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Influenza Treatment Sales Value Share by Type (2021-2026) Table 23. Global Influenza Treatment Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Pharmacies Table 25. Significant Companies of Online Pharmacies Table 26. Significant Companies of Retail Pharmacies Table 27. Global Influenza Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Influenza Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Influenza Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Influenza Treatment Sales Value Share by Application (2021-2026) Table 31. Global Influenza Treatment Sales Value Share by Application (2027-2032) Table 32. Global Influenza Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Influenza Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Influenza Treatment Sales Value Share by Region (2021-2026) Table 35. Global Influenza Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Influenza Treatment Sales Value Share by Region (2027-2032) Table 37. Global Influenza Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Influenza Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Influenza Treatment Sales Value Market Share by Country (2021-2026) Table 40. Global Influenza Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Influenza Treatment Sales Value Market Share by Country (2027-2032) Table 42. Sanofi Company Information Table 43. Sanofi Business Overview Table 44. Sanofi Influenza Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Sanofi Influenza Treatment Product Portfolio Table 46. Sanofi Recent Development Table 47. Novartis AG Company Information Table 48. Novartis AG Business Overview Table 49. Novartis AG Influenza Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Novartis AG Influenza Treatment Product Portfolio Table 51. Novartis AG Recent Development Table 52. GSK plc. Company Information Table 53. GSK plc. Business Overview Table 54. GSK plc. Influenza Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. GSK plc. Influenza Treatment Product Portfolio Table 56. GSK plc. Recent Development Table 57. Daiichi Sankyo Company Information Table 58. Daiichi Sankyo Business Overview Table 59. Daiichi Sankyo Influenza Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Daiichi Sankyo Influenza Treatment Product Portfolio Table 61. Daiichi Sankyo Recent Development Table 62. AstraZeneca Company Information Table 63. AstraZeneca Business Overview Table 64. AstraZeneca Influenza Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. AstraZeneca Influenza Treatment Product Portfolio Table 66. AstraZeneca Recent Development Table 67. Viatris Inc. (Mylan) Company Information Table 68. Viatris Inc. (Mylan) Business Overview Table 69. Viatris Inc. (Mylan) Influenza Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Viatris Inc. (Mylan) Influenza Treatment Product Portfolio Table 71. Viatris Inc. (Mylan) Recent Development Table 72. Teva Pharmaceutical Industries Ltd. Company Information Table 73. Teva Pharmaceutical Industries Ltd. Business Overview Table 74. Teva Pharmaceutical Industries Ltd. Influenza Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Teva Pharmaceutical Industries Ltd. Influenza Treatment Product Portfolio Table 76. Teva Pharmaceutical Industries Ltd. Recent Development Table 77. Roche Holding Company Information Table 78. Roche Holding Business Overview Table 79. Roche Holding Influenza Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Roche Holding Influenza Treatment Product Portfolio Table 81. Roche Holding Recent Development Table 82. NATCO Pharma Limited Company Information Table 83. NATCO Pharma Limited Business Overview Table 84. NATCO Pharma Limited Influenza Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. NATCO Pharma Limited Influenza Treatment Product Portfolio Table 86. NATCO Pharma Limited Recent Development Table 87. Gilead Sciences Company Information Table 88. Gilead Sciences Business Overview Table 89. Gilead Sciences Influenza Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Gilead Sciences Influenza Treatment Product Portfolio Table 91. Gilead Sciences Recent Development Table 92. BioCryst Pharmaceuticals Company Information Table 93. BioCryst Pharmaceuticals Business Overview Table 94. BioCryst Pharmaceuticals Influenza Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. BioCryst Pharmaceuticals Influenza Treatment Product Portfolio Table 96. BioCryst Pharmaceuticals Recent Development Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Influenza Treatment Product Image Figure 2. Global Influenza Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Influenza Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Zanamivir Image Figure 8. Peramivir Image Figure 9. Oseltamivir Phosphate Image Figure 10. Baloxavir Marboxil Image Figure 11. Others Image Figure 12. Global Influenza Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Influenza Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Influenza Treatment Sales Value Share by Type (2021-2032) Figure 15. Hospital Pharmacies Image Figure 16. Online Pharmacies Image Figure 17. Retail Pharmacies Image Figure 18. Global Influenza Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Influenza Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Influenza Treatment Sales Value Share by Application (2021-2032) Figure 21. Global Influenza Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Influenza Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Influenza Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. North America Influenza Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Influenza Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Influenza Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Influenza Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Influenza Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Influenza Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. South America Influenza Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Influenza Treatment Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Influenza Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Influenza Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Influenza Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Influenza Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Zanamivir
  • Peramivir
  • Oseltamivir Phosphate
  • Baloxavir Marboxil
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Sanofi
  • Novartis AG
  • GSK plc.
  • Daiichi Sankyo
  • AstraZeneca
  • Viatris Inc. (Mylan)
  • Teva Pharmaceutical Industries Ltd.
  • Roche Holding
  • NATCO Pharma Limited
  • Gilead Sciences
  • BioCryst Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Influenza Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Influenza Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Influenza Treatment Market Dynamics
  1. 2.1 Influenza Treatment Industry Trends
  2. 2.2 Influenza Treatment Industry Drivers
  3. 2.3 Influenza Treatment Industry Opportunities and Challenges
  4. 2.4 Influenza Treatment Industry Restraints
3 Influenza Treatment Market by Company
  1. 3.1 Global Influenza Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Influenza Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Influenza Treatment Company Ranking (2024-2026)
  4. 3.4 Global Influenza Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Influenza Treatment Company Product Type and Application
  6. 3.6 Global Influenza Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Influenza Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Influenza Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Influenza Treatment Market by Type
  1. 4.1 Influenza Treatment Type Introduction
  2. 4.1.1 Zanamivir
  3. 4.1.2 Peramivir
  4. 4.1.3 Oseltamivir Phosphate
  5. 4.1.4 Baloxavir Marboxil
  6. 4.1.5 Others
  7. 4.2 Global Influenza Treatment Sales Value by Type
  8. 4.2.1 Global Influenza Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Influenza Treatment Sales Value by Type (2021-2032)
  10. 4.2.3 Global Influenza Treatment Sales Value Share by Type (2021-2032)
5 Influenza Treatment Market by Application
  1. 5.1 Influenza Treatment Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Influenza Treatment Sales Value by Application
  6. 5.2.1 Global Influenza Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Influenza Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Influenza Treatment Sales Value Share by Application (2021-2032)
6 Influenza Treatment Regional Value Analysis
  1. 6.1 Global Influenza Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Influenza Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Influenza Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Influenza Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Influenza Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Influenza Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Influenza Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Influenza Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Influenza Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Influenza Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Influenza Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Influenza Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Influenza Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Influenza Treatment Sales Value Share by Country, 2025 VS 2032
7 Influenza Treatment Country-level Value Analysis
  1. 7.1 Global Influenza Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Influenza Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Influenza Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Influenza Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Influenza Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Influenza Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Influenza Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Influenza Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Influenza Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Influenza Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Influenza Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Influenza Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Influenza Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Influenza Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Influenza Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Influenza Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Influenza Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Influenza Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Influenza Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Influenza Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Influenza Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Influenza Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Influenza Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Influenza Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Influenza Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Influenza Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Influenza Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Influenza Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Influenza Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Influenza Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Influenza Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Influenza Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Influenza Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Influenza Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Influenza Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Influenza Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Influenza Treatment Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Influenza Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Influenza Treatment Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 GSK plc.
  14. 8.3.1 GSK plc. Company Information
  15. 8.3.2 GSK plc. Business Overview
  16. 8.3.3 GSK plc. Influenza Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GSK plc. Influenza Treatment Product Portfolio
  18. 8.3.5 GSK plc. Recent Developments
  19. 8.4 Daiichi Sankyo
  20. 8.4.1 Daiichi Sankyo Company Information
  21. 8.4.2 Daiichi Sankyo Business Overview
  22. 8.4.3 Daiichi Sankyo Influenza Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Daiichi Sankyo Influenza Treatment Product Portfolio
  24. 8.4.5 Daiichi Sankyo Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Influenza Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Influenza Treatment Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Viatris Inc. (Mylan)
  32. 8.6.1 Viatris Inc. (Mylan) Company Information
  33. 8.6.2 Viatris Inc. (Mylan) Business Overview
  34. 8.6.3 Viatris Inc. (Mylan) Influenza Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Viatris Inc. (Mylan) Influenza Treatment Product Portfolio
  36. 8.6.5 Viatris Inc. (Mylan) Recent Developments
  37. 8.7 Teva Pharmaceutical Industries Ltd.
  38. 8.7.1 Teva Pharmaceutical Industries Ltd. Company Information
  39. 8.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
  40. 8.7.3 Teva Pharmaceutical Industries Ltd. Influenza Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Teva Pharmaceutical Industries Ltd. Influenza Treatment Product Portfolio
  42. 8.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  43. 8.8 Roche Holding
  44. 8.8.1 Roche Holding Company Information
  45. 8.8.2 Roche Holding Business Overview
  46. 8.8.3 Roche Holding Influenza Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Roche Holding Influenza Treatment Product Portfolio
  48. 8.8.5 Roche Holding Recent Developments
  49. 8.9 NATCO Pharma Limited
  50. 8.9.1 NATCO Pharma Limited Company Information
  51. 8.9.2 NATCO Pharma Limited Business Overview
  52. 8.9.3 NATCO Pharma Limited Influenza Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 NATCO Pharma Limited Influenza Treatment Product Portfolio
  54. 8.9.5 NATCO Pharma Limited Recent Developments
  55. 8.10 Gilead Sciences
  56. 8.10.1 Gilead Sciences Company Information
  57. 8.10.2 Gilead Sciences Business Overview
  58. 8.10.3 Gilead Sciences Influenza Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Gilead Sciences Influenza Treatment Product Portfolio
  60. 8.10.5 Gilead Sciences Recent Developments
  61. 8.11 BioCryst Pharmaceuticals
  62. 8.11.1 BioCryst Pharmaceuticals Company Information
  63. 8.11.2 BioCryst Pharmaceuticals Business Overview
  64. 8.11.3 BioCryst Pharmaceuticals Influenza Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 BioCryst Pharmaceuticals Influenza Treatment Product Portfolio
  66. 8.11.5 BioCryst Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst